
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 30, 59, 7, 47 and 22 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 5, 3, 1 and 6 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides an overview of the Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline landscape.
Kidney cancer also called renal cancer is a disease in which kidney cells become malignant (cancerous) and grows out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, and anemia, shortness of breath and bone pain. Treatment includes surgery, radiation therapy and chemotherapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Cancer (Renal Cell Cancer) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 30, 59, 7, 47 and 22 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0 and Preclinical stages comprises 5, 3, 1 and 6 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Cancer (Renal Cell Cancer) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
315 Pages
- Introduction
- Global Markets Direct Report Coverage
- Kidney Cancer (Renal Cell Cancer) – Overview
- Kidney Cancer (Renal Cell Cancer) – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Kidney Cancer (Renal Cell Cancer) – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- ssessment by Route of Administration
- Assessment by Molecule Type
- Kidney Cancer (Renal Cell Cancer) – Companies Involved in Therapeutics Development
- 4D Pharma Plc
- 4SC AG
- A28 Therapeutics Inc
- AbbVie Inc
- Actuate Therapeutics Inc
- Adicet Bio Inc
- Affimed GmbH
- Agenus Inc
- Alligator Bioscience AB
- Almac Discovery Ltd
- Alpha-1 Biologics Corp
- Alphamab Oncology
- Alpine Immune Sciences Inc
- Anaveon AG
- AntiCancer Inc
- Apcure SAS
- Apollomics Inc
- Aravive Inc
- Astellas Pharma Inc
- AvenCell Europe GmbH
- Avesthagen Ltd
- Bavarian Nordic AS
- Bayer AG
- Beijing Foreland Pharma Co Ltd
- Beijing Scitech-MQ Pharmaceuticals Ltd
- BeyondSpring Inc
- Bio-Thera Solutions Ltd
- BioAtla Inc
- BioNTech SE
- Biosion Inc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Co
- Calviri Inc
- CanBas Co Ltd
- Canget BioTekpharma LLC
- Celldex Therapeutics Inc
- Centurion BioPharma Corp
- Chongqing Precision Biotech Co Ltd
- Clonz Biotech Pvt Ltd
- COARE Biotechnology Inc
- Coherent Biopharma
- Corvus Pharmaceuticals Inc
- Cothera Bioscience Pty Ltd
- CSPC Pharmaceutical Group Ltd
- CureLab Oncology Inc
- CytomX Therapeutics Inc
- Deciphera Pharmaceuticals Inc
- Deka Biosciences Inc
- DNAtrix Inc
- Duet Therapeutics Inc
- Dyadic International Inc
- Elevation Oncology Inc
- Enara Bio Ltd
- Exelixis Inc
- Fannin Innovation Studio
- Faron Pharmaceuticals Oy
- Gilead Sciences Inc
- Glycotope GmbH
- GSK plc
- Guangzhou BeBetter Medicine Technology Co Ltd
- Handa Pharmaceuticals LLC
- Helixmith Co Ltd
- ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
- ImmunityBio Inc
- Imugene Ltd
- Incyte Corp
- Inmune Bio Inc
- Innovative Cellular Therapeutics Co Ltd
- IO Biotech Inc
- iOmx Therapeutics AG
- Jiangxi Jemincare Group Co Ltd
- Johnson & Johnson
- Jubilant Therapeutics Inc
- Kind Pharmaceuticals
- Komipharm International Co Ltd
- Lantern Pharma Inc
- Luye Pharma Group Ltd
- MacroGenics Inc
- Marino Biotechnology Co Ltd
- MaxiVAX SA
- MdBioLab
- MedAnnex Ltd
- Merck & Co Inc
- Merck KGaA
- Metagone Biotech Inc
- Metis Precision Medicine
- MicuRx Pharmaceuticals Inc
- Midissia Therapeutics Inc
- Millennium Pharmaceuticals Inc
- Mina Therapeutics Ltd
- Mirati Therapeutics Inc
- Moleculin Biotech Inc
- Multitude therapeutics Inc
- Nanjing Aimeifei Biomedical Technology Co Ltd
- NanoVation Therapeutics Inc
- NeuClone Pty Ltd
- Novartis AG
- Oncolys BioPharma Inc
- Oncovir Inc
- OneThree Biotech Inc
- Orion Corp
- Orpheus Therapeutics Inc
- Panorama Researchama Research
- Pfizer Inc
- PharmaTher Holdings Ltd
- Pharmicell Co Ltd
- Pharminogen Inc
- Portage Biotech Inc
- Poseida Therapeutics Inc
- Propanc Biopharma Inc
- Pyxis Oncology Inc
- Qilu Pharmaceutical Co Ltd
- Qu Biologics Inc
- Quadriga BioSciences Inc
- RemeGen Co Ltd
- Repertoire Immune Medicines Inc
- Rizen (Suzhou) Biosciences Co Ltd
- SA Science Inc
- Sanofi
- Sareum Holdings Plc
- Scancell Holdings Plc
- Shanghai Escugen Biotechnology Co Ltd
- Shanghai Pharmaceutical Group Co Ltd
- Shanghai Pharmaceuticals Holding Co Ltd
- Shattuck Labs Inc
- Shenzhen Chipscreen Biosciences Co Ltd
- Shijiazhuang Yiling Pharmaceutical Co Ltd
- Sonnet BioTherapeutics Holdings Inc
- ST Pharm Co Ltd
- Statera Biopharma Inc
- Suzhou Stainwei Biotech Inc
- Suzhou Zerun New Drug Research and Development Co Ltd
- TAE Life Sciences LLC
- TotalClarity Inc
- UbiVac Inc
- Unicyte AG
- Vault Pharma Inc
- Versameb AG
- Wntrix Inc
- Xbrane Biopharma AB
- Yuhan Corp
- ZielBio Inc
- Zylem Biosciences Inc
- Kidney Cancer (Renal Cell Cancer) – Drug Profiles
- (IO-102 + IO-103) – Drug Profile
- (MG-005 + sorafenib) – Drug Profile
- 4SC-205 – Drug Profile
- ADI-004 – Drug Profile
- AFM-24I – Drug Profile
- AGEN-2373 – Drug Profile
- ALG.APV-527 – Drug Profile
- ALM-201 – Drug Profile
- Alpha-101 – Drug Profile
- amivantamab – Drug Profile
- AMT-707 – Drug Profile
- AND-021 – Drug Profile
- Annexuzlimab – Drug Profile
- Anti-MAGE-A3-DP4 T Cell Receptor (TCR) – Drug Profile
- ANV-419 – Drug Profile
- APC-004 – Drug Profile
- APL-502 – Drug Profile
- AutoSynVax – Drug Profile
- AVC-001 – Drug Profile
- BA-3151 – Drug Profile
- BAT-1306 – Drug Profile
- batiraxcept – Drug Profile
- BAY-2965501 – Drug Profile
- BCG-102 – Drug Profile
- BEBT-260 – Drug Profile
- bevacizumab biosimilar – Drug Profile
- bexmarilimab – Drug Profile
- BI-891065 – Drug Profile
- Bi-specific Monoclonal Antibody to Target 5T4 and CD3 for Oncology – Drug Profile
- bintrafusp alfa – Drug Profile
- Biologic for Delayed Graft Function, Diabetic Nephropathy, Kidney Disease, Non Alcoholic Steatohepatitis and Oncology – Drug Profile
- BMS-986315 – Drug Profile
- BNT-151 – Drug Profile
- BSI-060T – Drug Profile
- C-1360 – Drug Profile
- CBLB Immune Blocker – Drug Profile
- CBP-1018 – Drug Profile
- CBP-501 – Drug Profile
- CDX-1140 – Drug Profile
- Cell Therapy for Bladder and Renal Cancer – Drug Profile
- Cellgram for Oncology – Drug Profile
- Cellular Immunotherapy for Kidney Cancer – Drug Profile
- Cellular Immunotherapy for Oncology – Drug Profile
- Cellular Immunotherapy to Target HER-2 for Oncology – Drug Profile
- cetrelimab – Drug Profile
- CS-2164 – Drug Profile
- CTB-05 – Drug Profile
- CX-2029 – Drug Profile
- davoceticept – Drug Profile
- Diakine-DK1210 (EGFR) – Drug Profile
- Diakine-DK1510 (EGFR) – Drug Profile
- Diakine-DK710 (EGFR) – Drug Profile
- Diakine-DKIFN-Alpha10 (EGFR) – Drug Profile
- disitamab vedotin – Drug Profile
- DNA 1 – Drug Profile
- DNX-2440 – Drug Profile
- DPV-003 – Drug Profile
- Drugs to Inhibit DCLK1 Kinase for Oncology – Drug Profile
- DUET-02 – Drug Profile
- EEDVD-682 – Drug Profile
- Elenagen – Drug Profile
- elraglusib – Drug Profile
- englerin A – Drug Profile
- EP-300 – Drug Profile
- ESG-401 – Drug Profile
- ezabenlimab – Drug Profile
- FIS-103 – Drug Profile
- FL-496 – Drug Profile
- FP-208 – Drug Profile
- Gene Therapy 1 for Oncology – Drug Profile
- Gene Therapy for Oncology – Drug Profile
- Gene Therapy to Target MR1 for Oncology – Drug Profile
- Gene Therapy to Target NKG2D, Mesothelin and HER2 for Oncology – Drug Profile
- Gene Therapy to Target PD-L1 for Oncology – Drug Profile
- Gene Therapy to Target ROR2 for Kidney Cancer and Soft Tissue Sarcoma – Drug Profile
- GS-9716 – Drug Profile
- GSK-4381562 – Drug Profile
- HND-039 – Drug Profile
- HPV-19 – Drug Profile
- ICT-084 – Drug Profile
- ieramilimab – Drug Profile
- IMM-40H – Drug Profile
- IMT-07 – Drug Profile
- INCB-86550 – Drug Profile
- INKmune – Drug Profile
- IPG-7236 – Drug Profile
- ixazomib citrate – Drug Profile
- JBI-2174 – Drug Profile
- JMKX-003162 – Drug Profile
- JS-105 – Drug Profile
- Kidney – Drug Profile
- KN-046 – Drug Profile
- KN-052 – Drug Profile
- KN-383 – Drug Profile
- LADR-8 – Drug Profile
- larotrectinib sulfate – Drug Profile
- LP-184 – Drug Profile
- LY-01013 – Drug Profile
- M-9241 – Drug Profile
- metenkefalin – Drug Profile
- mitazalimab – Drug Profile
- MK-4830 – Drug Profile
- Modi-1 – Drug Profile
- MRX-15 – Drug Profile
- MRx-518 – Drug Profile
- MTL-CEBPA – Drug Profile
- mupadolimab – Drug Profile
- MvDN-30 – Drug Profile
- MVXONCO-1 – Drug Profile
- Nano Carbon Iron – Drug Profile
- nivolumab biosimilar – Drug Profile
- NSC-721689 – Drug Profile
- NSC-743380 – Drug Profile
- OBP-801 – Drug Profile
- ODM-203 – Drug Profile
- Oligonucleotide for Renal Cell Cancer – Drug Profile
- ONCase-PEG – Drug Profile
- Oncolytic Virus for Oncology – Drug Profile
- OSI-930 – Drug Profile
- OT-0010 – Drug Profile
- PAB-001 – Drug Profile
- PAX-1 – Drug Profile
- pegipanermin – Drug Profile
- pembrolizumab biosimilar – Drug Profile
- PF-07265807 – Drug Profile
- plinabulin – Drug Profile
- PMG-301 – Drug Profile
- PMUC1CALLO-1 – Drug Profile
- Poly-ICLC – Drug Profile
- PORT-6 – Drug Profile
- PORT-8 – Drug Profile
- PRP – Drug Profile
- PT-005 – Drug Profile
- PYX-201 – Drug Profile
- QBECP-SSI – Drug Profile
- QBS-10072S – Drug Profile
- QLF-31907 – Drug Profile
- Recombinant Protein for Oncology – Drug Profile
- Renal Medullary Carcinoma (RMC) Therapeutic – Drug Profile
- ribociclib succinate – Drug Profile
- rogaratinib – Drug Profile
- RPTR-147 – Drug Profile
- sacituzumab govitecan – Drug Profile
- SAR-442720 – Drug Profile
- SB-02024 – Drug Profile
- SDC-1802 – Drug Profile
- serclutamab talirine – Drug Profile
- seribantumab – Drug Profile
- sitravatinib malate – Drug Profile
- SL-279252 – Drug Profile
- SON-1410 – Drug Profile
- SON-2014 – Drug Profile
- SPH-3348 – Drug Profile
- SRD-4406 – Drug Profile
- ST-1898 – Drug Profile
- STP-061002 – Drug Profile
- SYHA-1813 – Drug Profile
- talazoparib – Drug Profile
- Target 2 – Drug Profile
- TCONC-511 – Drug Profile
- tepotinib hydrochloride – Drug Profile
- tomuzotuximab – Drug Profile
- tucidinostat – Drug Profile
- urelumab – Drug Profile
- Vaccine for Oncology 1 – Drug Profile
- Vaccine to Target Brachyury for Oncology – Drug Profile
- VAXINIA – Drug Profile
- VM-804 – Drug Profile
- VPI-101 – Drug Profile
- WP-1066 – Drug Profile
- WTX-202 – Drug Profile
- XB-002 – Drug Profile
- XY-0206 – Drug Profile
- YHC-1112 – Drug Profile
- YS-001 – Drug Profile
- ZB-520 – Drug Profile
- ZYL-001 – Drug Profile
- Kidney Cancer (Renal Cell Cancer) – Dormant Projects
- Kidney Cancer (Renal Cell Cancer) – Discontinued Products
- Kidney Cancer (Renal Cell Cancer) – Product Development Milestones
- Featured News & Press Releases
- Dec 01, 2022: Pyxis Oncology announces IND clearance from FDA for PYX-106
- Mar 03, 2022: Aravive announces positive updated data and new biomarker data from phase 1b study of Batiraxcept in Clear Cell Renal Cell Carcinoma
- Mar 02, 2022: Aravive to present updated modeling data from Batiraxcept clinical trials at the AACR Annual Meeting
- Dec 08, 2021: Alpha-1 Biologics announces positive data published in frontiers in Oncology on Alphataxin in combination with anti-PD-1 therapy that suppressed murine renal cancer and metastasis
- Oct 07, 2021: US patent granted for Sareum's SDC-1802 TYK2/JAK1 inhibitor
- Aug 30, 2021: Sonnet announces successful completion of the discovery phase for its next preclinical pipeline candidate (SON-1410)
- Jul 30, 2021: US Patent Notice of Allowance for Sareum’s SDC-1802
- Dec 31, 2020: Aravive announces board member transition to advisory role
- Nov 03, 2020: CSPC Pharmaceutical Group : Voluntary announcement innovative drug “SYHA1813 oral solutions” obtains clinical trial approval
- Sep 15, 2020: Panorama Researchama Research receives a grant of $101,250 from Department of Defense
- Oct 17, 2019: Sareum Holdings -Research Update -AACR-NCI-EORTC abstract
- Sep 26, 2018: Sareum Holdings: Potent, selective small molecule inhibitor of TYK2/JAK1 selected for further development as potential treatment for certain types of leukaemia, lymphoma and solid tumour
- Jul 31, 2018: Approval for clinical trial for class I new chemical drug—Anti-Tumor innovative drug (LY01013) in China
- Nov 09, 2009: Keryx Biopharmaceuticals Presented Data From Phase I Study Of Perifosine In Combination With Sorafenib At The 25th Annual Chemotherapy Foundation Symposium
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
- Table 10: Number of Products under Development by Universities/Institutes, 2022
- Table 11: Products under Development by Companies, 2022
- Table 12: Products under Development by Companies, 2022 (Contd..1)
- Table 13: Products under Development by Companies, 2022 (Contd..2)
- Table 14: Products under Development by Companies, 2022 (Contd..3)
- Table 15: Products under Development by Companies, 2022 (Contd..4)
- Table 16: Products under Development by Companies, 2022 (Contd..5)
- Table 17: Products under Development by Companies, 2022 (Contd..6)
- Table 18: Products under Development by Companies, 2022 (Contd..7)
- Table 19: Products under Development by Companies, 2022 (Contd..8)
- Table 20: Products under Development by Universities/Institutes, 2022
- Table 21: Number of Products by Stage and Target, 2022
- Table 22: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 23: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 24: Number of Products by Stage and Target, 2022 (Contd..3)
- Table 25: Number of Products by Stage and Target, 2022 (Contd..4)
- Table 26: Number of Products by Stage and Target, 2022 (Contd..5)
- Table 27: Number of Products by Stage and Mechanism of Action, 2022
- Table 28: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 29: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 30: Number of Products by Stage and Mechanism of Action, 2022 (Contd..3)
- Table 31: Number of Products by Stage and Mechanism of Action, 2022 (Contd..4)
- Table 32: Number of Products by Stage and Mechanism of Action, 2022 (Contd..5)
- Table 33: Number of Products by Stage and Route of Administration, 2022
- Table 34: Number of Products by Stage and Molecule Type, 2022
- Table 35: Kidney Cancer (Renal Cell Cancer) – Pipeline by 4D Pharma Plc, 2022
- Table 36: Kidney Cancer (Renal Cell Cancer) – Pipeline by 4SC AG, 2022
- Table 37: Kidney Cancer (Renal Cell Cancer) – Pipeline by A28 Therapeutics Inc, 2022
- Table 38: Kidney Cancer (Renal Cell Cancer) – Pipeline by AbbVie Inc, 2022
- Table 39: Kidney Cancer (Renal Cell Cancer) – Pipeline by Actuate Therapeutics Inc, 2022
- Table 40: Kidney Cancer (Renal Cell Cancer) – Pipeline by Adicet Bio Inc, 2022
- Table 41: Kidney Cancer (Renal Cell Cancer) – Pipeline by Affimed GmbH, 2022
- Table 42: Kidney Cancer (Renal Cell Cancer) – Pipeline by Agenus Inc, 2022
- Table 43: Kidney Cancer (Renal Cell Cancer) – Pipeline by Alligator Bioscience AB, 2022
- Table 44: Kidney Cancer (Renal Cell Cancer) – Pipeline by Almac Discovery Ltd, 2022
- Table 45: Kidney Cancer (Renal Cell Cancer) – Pipeline by Alpha-1 Biologics Corp, 2022
- Table 46: Kidney Cancer (Renal Cell Cancer) – Pipeline by Alphamab Oncology, 2022
- Table 47: Kidney Cancer (Renal Cell Cancer) – Pipeline by Alpine Immune Sciences Inc, 2022
- Table 48: Kidney Cancer (Renal Cell Cancer) – Pipeline by Anaveon AG, 2022
- Table 49: Kidney Cancer (Renal Cell Cancer) – Pipeline by AntiCancer Inc, 2022
- Table 50: Kidney Cancer (Renal Cell Cancer) – Pipeline by Apcure SAS, 2022
- Table 51: Kidney Cancer (Renal Cell Cancer) – Pipeline by Apollomics Inc, 2022
- Table 52: Kidney Cancer (Renal Cell Cancer) – Pipeline by Aravive Inc, 2022
- Table 53: Kidney Cancer (Renal Cell Cancer) – Pipeline by Astellas Pharma Inc, 2022
- Table 54: Kidney Cancer (Renal Cell Cancer) – Pipeline by AvenCell Europe GmbH, 2022
- Table 55: Kidney Cancer (Renal Cell Cancer) – Pipeline by Avesthagen Ltd, 2022
- Table 56: Kidney Cancer (Renal Cell Cancer) – Pipeline by Bavarian Nordic AS, 2022
- Table 57: Kidney Cancer (Renal Cell Cancer) – Pipeline by Bayer AG, 2022
- Table 58: Kidney Cancer (Renal Cell Cancer) – Pipeline by Beijing Foreland Pharma Co Ltd, 2022
- Table 59: Kidney Cancer (Renal Cell Cancer) – Pipeline by Beijing Scitech-MQ Pharmaceuticals Ltd, 2022
- Table 60: Kidney Cancer (Renal Cell Cancer) – Pipeline by BeyondSpring Inc, 2022
- Table 61: Kidney Cancer (Renal Cell Cancer) – Pipeline by Bio-Thera Solutions Ltd, 2022
- Table 62: Kidney Cancer (Renal Cell Cancer) – Pipeline by BioAtla Inc, 2022
- Table 63: Kidney Cancer (Renal Cell Cancer) – Pipeline by BioNTech SE, 2022
- Table 64: Kidney Cancer (Renal Cell Cancer) – Pipeline by Biosion Inc, 2022
- Table 65: Kidney Cancer (Renal Cell Cancer) – Pipeline by Boehringer Ingelheim International GmbH, 2022
- Table 66: Kidney Cancer (Renal Cell Cancer) – Pipeline by Bristol-Myers Squibb Co, 2022
- Table 67: Kidney Cancer (Renal Cell Cancer) – Pipeline by Calviri Inc, 2022
- Table 68: Kidney Cancer (Renal Cell Cancer) – Pipeline by CanBas Co Ltd, 2022
- Table 69: Kidney Cancer (Renal Cell Cancer) – Pipeline by Canget BioTekpharma LLC, 2022
- Table 70: Kidney Cancer (Renal Cell Cancer) – Pipeline by Celldex Therapeutics Inc, 2022
- Table 71: Kidney Cancer (Renal Cell Cancer) – Pipeline by Centurion BioPharma Corp, 2022
- Table 72: Kidney Cancer (Renal Cell Cancer) – Pipeline by Chongqing Precision Biotech Co Ltd, 2022
- Table 73: Kidney Cancer (Renal Cell Cancer) – Pipeline by Clonz Biotech Pvt Ltd, 2022
- Table 74: Kidney Cancer (Renal Cell Cancer) – Pipeline by COARE Biotechnology Inc, 2022
- Table 75: Kidney Cancer (Renal Cell Cancer) – Pipeline by Coherent Biopharma, 2022
- Table 76: Kidney Cancer (Renal Cell Cancer) – Pipeline by Corvus Pharmaceuticals Inc, 2022
- Table 77: Kidney Cancer (Renal Cell Cancer) – Pipeline by Cothera Bioscience Pty Ltd, 2022
- Table 78: Kidney Cancer (Renal Cell Cancer) – Pipeline by CSPC Pharmaceutical Group Ltd, 2022
- Table 79: Kidney Cancer (Renal Cell Cancer) – Pipeline by CureLab Oncology Inc, 2022
- Table 80: Kidney Cancer (Renal Cell Cancer) – Pipeline by CytomX Therapeutics Inc, 2022
- Table 81: Kidney Cancer (Renal Cell Cancer) – Pipeline by Deciphera Pharmaceuticals Inc, 2022
- Table 82: Kidney Cancer (Renal Cell Cancer) – Pipeline by Deka Biosciences Inc, 2022
- Table 83: Kidney Cancer (Renal Cell Cancer) – Pipeline by DNAtrix Inc, 2022
- Table 84: Kidney Cancer (Renal Cell Cancer) – Pipeline by Duet Therapeutics Inc, 2022
- Table 85: Kidney Cancer (Renal Cell Cancer) – Pipeline by Dyadic International Inc, 2022
- Table 86: Kidney Cancer (Renal Cell Cancer) – Pipeline by Elevation Oncology Inc, 2022
- Table 87: Kidney Cancer (Renal Cell Cancer) – Pipeline by Enara Bio Ltd, 2022
- Table 88: Kidney Cancer (Renal Cell Cancer) – Pipeline by Exelixis Inc, 2022
- Table 89: Kidney Cancer (Renal Cell Cancer) – Pipeline by Fannin Innovation Studio, 2022
- Table 90: Kidney Cancer (Renal Cell Cancer) – Pipeline by Faron Pharmaceuticals Oy, 2022
- Table 91: Kidney Cancer (Renal Cell Cancer) – Pipeline by Gilead Sciences Inc, 2022
- Table 92: Kidney Cancer (Renal Cell Cancer) – Pipeline by Glycotope GmbH, 2022
- Table 93: Kidney Cancer (Renal Cell Cancer) – Pipeline by GSK plc, 2022
- Table 94: Kidney Cancer (Renal Cell Cancer) – Pipeline by Guangzhou BeBetter Medicine Technology Co Ltd, 2022
- Table 95: Kidney Cancer (Renal Cell Cancer) – Pipeline by Handa Pharmaceuticals LLC, 2022
- Table 96: Kidney Cancer (Renal Cell Cancer) – Pipeline by Helixmith Co Ltd, 2022
- Table 97: Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, 2022
- Table 98: Kidney Cancer (Renal Cell Cancer) – Pipeline by ImmunityBio Inc, 2022
- Table 99: Kidney Cancer (Renal Cell Cancer) – Pipeline by Imugene Ltd, 2022
- Table 100: Kidney Cancer (Renal Cell Cancer) – Pipeline by Incyte Corp, 2022
- Table 101: Kidney Cancer (Renal Cell Cancer) – Pipeline by Inmune Bio Inc, 2022
- Table 102: Kidney Cancer (Renal Cell Cancer) – Pipeline by Innovative Cellular Therapeutics Co Ltd, 2022
- Table 103: Kidney Cancer (Renal Cell Cancer) – Pipeline by IO Biotech Inc, 2022
- Table 104: Kidney Cancer (Renal Cell Cancer) – Pipeline by iOmx Therapeutics AG, 2022
- Table 105: Kidney Cancer (Renal Cell Cancer) – Pipeline by Jiangxi Jemincare Group Co Ltd, 2022
- Table 106: Kidney Cancer (Renal Cell Cancer) – Pipeline by Johnson & Johnson, 2022
- Table 107: Kidney Cancer (Renal Cell Cancer) – Pipeline by Jubilant Therapeutics Inc, 2022
- Table 108: Kidney Cancer (Renal Cell Cancer) – Pipeline by Kind Pharmaceuticals, 2022
- Table 109: Kidney Cancer (Renal Cell Cancer) – Pipeline by Komipharm International Co Ltd, 2022
- Table 110: Kidney Cancer (Renal Cell Cancer) – Pipeline by Lantern Pharma Inc, 2022
- Table 111: Kidney Cancer (Renal Cell Cancer) – Pipeline by Luye Pharma Group Ltd, 2022
- Table 112: Kidney Cancer (Renal Cell Cancer) – Pipeline by MacroGenics Inc, 2022
- Table 113: Kidney Cancer (Renal Cell Cancer) – Pipeline by Marino Biotechnology Co Ltd, 2022
- Table 114: Kidney Cancer (Renal Cell Cancer) – Pipeline by MaxiVAX SA, 2022
- Table 115: Kidney Cancer (Renal Cell Cancer) – Pipeline by MdBioLab, 2022
- Table 116: Kidney Cancer (Renal Cell Cancer) – Pipeline by MedAnnex Ltd, 2022
- Table 117: Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck & Co Inc, 2022
- Table 118: Kidney Cancer (Renal Cell Cancer) – Pipeline by Merck KGaA, 2022
- Table 119: Kidney Cancer (Renal Cell Cancer) – Pipeline by Metagone Biotech Inc, 2022
- Table 120: Kidney Cancer (Renal Cell Cancer) – Pipeline by Metis Precision Medicine, 2022
- Table 121: Kidney Cancer (Renal Cell Cancer) – Pipeline by MicuRx Pharmaceuticals Inc, 2022
- Table 122: Kidney Cancer (Renal Cell Cancer) – Pipeline by Midissia Therapeutics Inc, 2022
- Table 123: Kidney Cancer (Renal Cell Cancer) – Pipeline by Millennium Pharmaceuticals Inc, 2022
- Table 124: Kidney Cancer (Renal Cell Cancer) – Pipeline by Mina Therapeutics Ltd, 2022
- Table 125: Kidney Cancer (Renal Cell Cancer) – Pipeline by Mirati Therapeutics Inc, 2022
- Table 126: Kidney Cancer (Renal Cell Cancer) – Pipeline by Moleculin Biotech Inc, 2022
- Table 127: Kidney Cancer (Renal Cell Cancer) – Pipeline by Multitude therapeutics Inc, 2022
- Table 128: Kidney Cancer (Renal Cell Cancer) – Pipeline by Nanjing Aimeifei Biomedical Technology Co Ltd, 2022
- Table 129: Kidney Cancer (Renal Cell Cancer) – Pipeline by NanoVation Therapeutics Inc, 2022
- Table 130: Kidney Cancer (Renal Cell Cancer) – Pipeline by NeuClone Pty Ltd, 2022
- Table 131: Kidney Cancer (Renal Cell Cancer) – Pipeline by Novartis AG, 2022
- Table 132: Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncolys BioPharma Inc, 2022
- Table 133: Kidney Cancer (Renal Cell Cancer) – Pipeline by Oncovir Inc, 2022
- Table 134: Kidney Cancer (Renal Cell Cancer) – Pipeline by OneThree Biotech Inc, 2022
- Table 135: Kidney Cancer (Renal Cell Cancer) – Pipeline by Orion Corp, 2022
- Table 136: Kidney Cancer (Renal Cell Cancer) – Pipeline by Orpheus Therapeutics Inc, 2022
- Table 137: Kidney Cancer (Renal Cell Cancer) – Pipeline by Panorama Researchama Research, 2022
- Table 138: Kidney Cancer (Renal Cell Cancer) – Pipeline by Pfizer Inc, 2022
- Table 139: Kidney Cancer (Renal Cell Cancer) – Pipeline by PharmaTher Holdings Ltd, 2022
- Table 140: Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharmicell Co Ltd, 2022
- Table 141: Kidney Cancer (Renal Cell Cancer) – Pipeline by Pharminogen Inc, 2022
- Table 142: Kidney Cancer (Renal Cell Cancer) – Pipeline by Portage Biotech Inc, 2022
- Table 143: Kidney Cancer (Renal Cell Cancer) – Pipeline by Poseida Therapeutics Inc, 2022
- Table 144: Kidney Cancer (Renal Cell Cancer) – Pipeline by Propanc Biopharma Inc, 2022
- Table 145: Kidney Cancer (Renal Cell Cancer) – Pipeline by Pyxis Oncology Inc, 2022
- Table 146: Kidney Cancer (Renal Cell Cancer) – Pipeline by Qilu Pharmaceutical Co Ltd, 2022
- Table 147: Kidney Cancer (Renal Cell Cancer) – Pipeline by Qu Biologics Inc, 2022
- Table 148: Kidney Cancer (Renal Cell Cancer) – Pipeline by Quadriga BioSciences Inc, 2022
- Table 149: Kidney Cancer (Renal Cell Cancer) – Pipeline by RemeGen Co Ltd, 2022
- Table 150: Kidney Cancer (Renal Cell Cancer) – Pipeline by Repertoire Immune Medicines Inc, 2022
- Table 151: Kidney Cancer (Renal Cell Cancer) – Pipeline by Rizen (Suzhou) Biosciences Co Ltd, 2022
- Table 152: Kidney Cancer (Renal Cell Cancer) – Pipeline by SA Science Inc, 2022
- Table 153: Kidney Cancer (Renal Cell Cancer) – Pipeline by Sanofi, 2022
- Table 154: Kidney Cancer (Renal Cell Cancer) – Pipeline by Sareum Holdings Plc, 2022
- Table 155: Kidney Cancer (Renal Cell Cancer) – Pipeline by Scancell Holdings Plc, 2022
- Table 156: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shanghai Escugen Biotechnology Co Ltd, 2022
- Table 157: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shanghai Pharmaceutical Group Co Ltd, 2022
- Table 158: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shanghai Pharmaceuticals Holding Co Ltd, 2022
- Table 159: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shattuck Labs Inc, 2022
- Table 160: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2022
- Table 161: Kidney Cancer (Renal Cell Cancer) – Pipeline by Shijiazhuang Yiling Pharmaceutical Co Ltd, 2022
- Table 162: Kidney Cancer (Renal Cell Cancer) – Pipeline by Sonnet BioTherapeutics Holdings Inc, 2022
- Table 163: Kidney Cancer (Renal Cell Cancer) – Pipeline by ST Pharm Co Ltd, 2022
- Table 164: Kidney Cancer (Renal Cell Cancer) – Pipeline by Statera Biopharma Inc, 2022
- Table 165: Kidney Cancer (Renal Cell Cancer) – Pipeline by Suzhou Stainwei Biotech Inc, 2022
- Table 166: Kidney Cancer (Renal Cell Cancer) – Pipeline by Suzhou Zerun New Drug Research and Development Co Ltd, 2022
- Table 167: Kidney Cancer (Renal Cell Cancer) – Pipeline by TAE Life Sciences LLC, 2022
- Table 168: Kidney Cancer (Renal Cell Cancer) – Pipeline by TotalClarity Inc, 2022
- Table 169: Kidney Cancer (Renal Cell Cancer) – Pipeline by UbiVac Inc, 2022
- Table 170: Kidney Cancer (Renal Cell Cancer) – Pipeline by Unicyte AG, 2022
- Table 171: Kidney Cancer (Renal Cell Cancer) – Pipeline by Vault Pharma Inc, 2022
- Table 172: Kidney Cancer (Renal Cell Cancer) – Pipeline by Versameb AG, 2022
- Table 173: Kidney Cancer (Renal Cell Cancer) – Pipeline by Wntrix Inc, 2022
- Table 174: Kidney Cancer (Renal Cell Cancer) – Pipeline by Xbrane Biopharma AB, 2022
- Table 175: Kidney Cancer (Renal Cell Cancer) – Pipeline by Yuhan Corp, 2022
- Table 176: Kidney Cancer (Renal Cell Cancer) – Pipeline by ZielBio Inc, 2022
- Table 177: Kidney Cancer (Renal Cell Cancer) – Pipeline by Zylem Biosciences Inc, 2022
- Table 178: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022
- Table 179: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022 (Contd..1)
- Table 180: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022 (Contd..2)
- Table 181: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022 (Contd..3)
- Table 182: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022 (Contd..4)
- Table 183: Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022 (Contd..5)
- Table 184: Kidney Cancer (Renal Cell Cancer) – Discontinued Products, 2022
- List of Figures
- Figure 1: Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products under Development by Universities/Institutes, 2022
- Figure 4: Number of Products by Top 10 Targets, 2022
- Figure 5: Number of Products by Stage and Top 10 Targets, 2022
- Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 8: Number of Products by Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 10: Number of Products by Top 10 Molecule Types, 2022
- Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.